NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors

NewAmsterdam Pharma Co N.V.

Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.
Errors: weighted average ordinary shares outstanding incorrectly used ending shares instead of weighted average.
Restatement affects only IFRS-based financials in 2022 Annual Report; 2023 US GAAP financials not impacted.
Company intends to file amendment to 2022 Annual Report as soon as practicable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.